Pharma News, 2024

GSK has announced that Jemperli (dostarlimab) plus chemotherapy has obtained expanded approval from the US Food and Drug Administration (FDA) for treating adult patients with primary a...

Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma.

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease. Biogen and Eisai’s Alzheimer’s disease (AD) drug has shown continued benefits in...

Plasma phosphorylated (p)-tau217 testing can help identify preclinical Alzheimer's disease (AD), which could aid clinical trial recruitment. Study shows that plasma p-tau217, alone...

Clinical trial trends point to studying combination therapies and lifestyle changes using alternate designs in Alzheimer’s research.

Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of...

The US Food and Drug Administration (FDA) has approved Luye Pharma’s ERZOFRI (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia in adu...

When conserving scarce financial resources, biotechs often favor their assets that have made the most progress through the clinic.

Developed by Merck & Co., the blockbuster therapeutic antibody Keytruda (pembrolizumab) was first approved by the FDA in 2014 to treat several types of cancer.

Sage Therapeutics (SAGE) said Wednesday its Biogen (BIIB)-partnered treatment for essential tremor failed in a Phase 2 study, leading Sage stock to collapse.

From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S....

Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of pre-exposure prophylaxis (PrEP) lenacapavir at the world’s largest H...